Dr Reddy's completes the acquisition of Wockhardt's select

The business comprises a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, Pain and Vaccines, which would transfer to Dr Reddy's along with related sales and marketing teams and a manufacturing plant located in Baddi, Himachal Pradesh with all plant employees, a press release from the drug maker said. 

On February 12, 2020, Dr.Reddys signed a Business Transfer Agreement(BTA) with Wockhardt to acquire the above- referred business undertakingfor an upfront consideration of Rs 1,850 crorec. In view of the COVID-19 pandemic and the consequent government restrictions, there has been a reduction in the revenue from the sales of the products forming part of the Business Undertaking during March and April 2020, it said. 

Subsequently, through an amendment to the BTA, Dr.Reddy's and Wockhardt that 1,483 crore would be paid on the date of closing the deal consideration, and the rest would be through different ways,the release said. G V Prasad, Co-Chairman and Managing Director of Dr. Reddy's said this deal is in line with the company's strategic focus on India and has paved a path for accelerated growth and leadership in the domestic market. "We believe that the acquired portfolio offers a good growth potential for us. We welcome the employees joining us from Wockhardt to the family of Dr.Reddys," Prasad said.